tldrdailynews.com logo
Tag

Ivonescimab

All articles tagged with #ivonescimab

SMMT Climbs on Ivonescimab Survival Edge as Keytruda Rivalry Intensifies
business1 month ago

SMMT Climbs on Ivonescimab Survival Edge as Keytruda Rivalry Intensifies

Summit Therapeutics (SMMT) surged after ASCO data showed Ivonescimab plus chemotherapy extended overall survival in advanced squamous NSCLC to 27.9 months vs 23.7 with a PD-1 inhibitor, with about 65% alive at two years versus 49% in the control. The results, independent of PD-L1 status, fuel investor optimism about Ivonescimab as a potential successor to Keytruda and have Pfizer, Bristol Myers Squibb, and Merck pursuing rival PD-(L)1xVEGF therapies. SMMT also has an FDA review for Ivonescimab in EGFR-mutated lung cancer, while retail sentiment on Stocktwits turned extremely bullish despite some regulatory questions about China-sourced data. Big Pharma stocks mostly declined overnight.

via Yahoo Finance|
#asco#business#ivonescimab
Ivonescimab+chemo extends survival in first-line squamous NSCLC at ASCO
health1 month ago

Ivonescimab+chemo extends survival in first-line squamous NSCLC at ASCO

Akeso’s ivonescimab, a PD-1xVEGF bispecific, plus chemotherapy significantly extended overall survival in first-line, untreated squamous NSCLC in the Harmoni-6 trial, cutting death risk by 34% with a median OS of 27.9 months vs 23.7 months (p=0.0017) versus Tevimbra-chemo. The interim China-only ASCO presentation showed benefit across PD-L1–negative and –positive patients, but experts caution the follow-up is immature and point to safety signals and trial eligibility criteria that may limit global applicability, signaling a need for further studies.

via Fierce Pharma|
#harmoni-6#health#ivonescimab
Regional Data Variability Challenges Summit's Lung Cancer Drug and Keytruda Rival
health10 months ago

Regional Data Variability Challenges Summit's Lung Cancer Drug and Keytruda Rival

Summit Therapeutics' lung cancer drug ivonescimab showed promising overall survival and progression-free survival results in a Phase 3 trial, but regional differences, especially between Western and Chinese patients, have raised concerns about its competitive potential against Merck's Keytruda, leading to a decline in the company's stock.

via Yahoo Finance|
#clinical-trial#health#ivonescimab
Summit Therapeutics' Mixed Results and Market Impact in Oncology Trials
healthcare1 year ago

Summit Therapeutics' Mixed Results and Market Impact in Oncology Trials

A Phase 3 trial of the drug ivonescimab, which targets PD-1 and VEGF pathways, showed it delayed tumor progression in lung cancer patients but did not significantly extend survival, potentially complicating its path to FDA approval in the US. The results highlight the challenges of demonstrating survival benefits for cancer drugs, despite promising progression-free survival data.

via BioPharma Dive|
#cancer#fda-approval#healthcare
Biotech Trials and Market Reactions: A Mixed Bag for Summit and Rivals
business1 year ago

Biotech Trials and Market Reactions: A Mixed Bag for Summit and Rivals

Summit Therapeutics' cancer drug trial results showed mixed outcomes, with the drug performing better than placebo in delaying cancer progression and working equally well in Asian and Western patients, but failing to demonstrate a statistically significant increase in overall survival. Despite the disappointing results, analysts viewed the trial as a positive sign for Chinese biopharma collaborations, though the company's stock dropped significantly due to concerns over FDA approval requirements.

via Barron's|
#business#cancer-drug-trial#chinese-biopharma
Summit's Lung Cancer Drugs Show Mixed Results in Global Trials
healthcare1 year ago

Summit's Lung Cancer Drugs Show Mixed Results in Global Trials

Akeso and Summit Therapeutics' drug ivonescimab showed promising results in delaying progression of certain lung cancers in a global phase 3 trial, with significant improvements in progression-free survival, though overall survival benefits are still being evaluated. The drug demonstrated consistent effects across Asian and Western populations, and the companies plan to seek FDA approval, despite some investor disappointment over the overall survival data.

via Fierce Pharma|
#healthcare#ivonescimab#lung-cancer
Summit Therapeutics' Ivonescimab Outperforms Keytruda in China Lung Cancer Trial, Shares Triple
health2 years ago

Summit Therapeutics' Ivonescimab Outperforms Keytruda in China Lung Cancer Trial, Shares Triple

Summit Therapeutics' Phase 3 HARMONi-2 study in China showed that their lung cancer therapy ivonescimab significantly improved progression-free survival compared to Merck's Keytruda in patients with advanced non-small cell lung cancer. Despite this positive result, Summit's stock saw a decline after a significant rise the previous day.

via Yahoo Finance|
#clinical-trial#health#ivonescimab
Summit Therapeutics Stock Skyrockets After Cancer Drug Outperforms Keytruda
businesshealth2 years ago

Summit Therapeutics Stock Skyrockets After Cancer Drug Outperforms Keytruda

Summit Therapeutics Inc. shares soared 272% after a late-stage trial showed their cancer drug ivonescimab significantly outperformed Merck's Keytruda in treating non-small cell lung cancer, leading to a decline in Merck's shares. The trial, conducted in China, demonstrated a meaningful improvement in progression-free survival, with analysts optimistic about the drug's potential in other populations and across multiple solid tumors.

via Yahoo Finance|
#businesshealth#cancer-drug#ivonescimab